Oncopeptides Shows Promising Growth as It Pursues Profitability by 2026

Oncopeptides, a biotech company specializing in treatments for hard-to-treat cancers, is experiencing significant growth, showcasing over 30% growth for three consecutive quarters and impressive 135% annual growth as per their Q2 report. CEO Sofia Heigis expressed optimism about reaching profitability by the end of 2026, driven by robust sales growth primarily in major markets like Germany, Spain, and Italy.

In Q2, Oncopeptides reported a 45% increase in sales compared to the previous quarter, fueled by the success of its flagship drug, Pepaxti, which has gained credibility after being included in European treatment guidelines for multiple myeloma. The company's market penetration is noteworthy, with 97% of regions in Spain and 80% in Italy accessible, aided by dedicated sales teams and strong collaborations with healthcare providers.

Oncopeptides is currently conducting a guaranteed rights issue to accelerate its sales efforts in Europe and to invest in its drug pipeline, which includes new candidates such as OPD5 and OPDC3. The potential market value in its top four markets is estimated to be around 1.5 billion SEK. Additionally, discussions are underway for launching Pepaxti in Japan while maintaining an existing partnership in South Korea. Heigis also highlighted how successful outcomes with Pepaxti could significantly enhance confidence in their other drug candidates, ensuring a broader impact in the cancer treatment landscape.